Merger & Acquisition
Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug
About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1
Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.
Drugmakers are becoming much more cautious with their budgets, WebMD executives said.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Merck and Allergan reportedly vying to buy Biogen; drugmakers fight California measure capping drug prices; few seniors use the web to look for health info
Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's
WPP's acquisition of CMI, a significant player in the healthcare media-planning space, will likely bolster the services it provides to pharma clients.
Viscira, a digital marketing agency, works with GlaxoSmithKline, Merck, and Genentech, among other life-sciences companies.
DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.
J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies